The price difference between Wegovy and Zepbound is rarely the thing that decides what you pay. Both carry list prices above a thousand dollars a month, and almost nobody pays list. What you actually pay is set by whether your plan covers weight management at all, whether you qualify for a manufacturer savings card, and which self-pay route you use if coverage is denied. Two people prescribed the same drug in the same month can pay amounts that differ by an order of magnitude.
Coverage is a category decision, not a drug decision
Most commercial plans treat anti-obesity medication as a benefit category that is either included or excluded. When it is excluded, both Wegovy and Zepbound are excluded together, and comparing their relative prices is beside the point. When it is included, both are usually on formulary somewhere, and the meaningful variable becomes tier placement and prior authorization rather than which molecule costs more.
This is why checking the category first saves time. Ask whether the plan covers medication for chronic weight management, not whether it covers a specific brand. If the answer is no, the next question is what self-pay costs, and the brand comparison restarts on completely different numbers.
Medicare adds a further wrinkle. Part D has historically been prohibited from covering drugs used solely for weight loss, which is why coverage conversations for older patients often turn on whether there is a separate qualifying indication rather than on the obesity indication itself.
The four routes to a price
| Route | What determines the number | Main limitation |
|---|---|---|
| Covered benefit | Formulary tier, deductible, coinsurance | Requires the plan to cover the category at all |
| Manufacturer savings card | Commercial insurance status and eligibility rules | Usually excludes government insurance |
| Manufacturer self-pay program | Fixed cash price set by the manufacturer | Conditions on refill timing and dose |
| Compounded medication | Pharmacy and provider pricing | Not an FDA-approved product |
Savings cards are narrower than they appear
Both manufacturers run savings programs, and both are commonly misread. The headline figure typically assumes commercial insurance that already covers the drug, with the card reducing the remaining copay. A person whose plan excludes the category usually does not qualify for the largest advertised reduction, and people on Medicare or Medicaid are generally excluded from commercial copay assistance entirely.
The practical step is to read the eligibility conditions before treating an advertised price as your price. The number that matters is what the card produces given your specific coverage status, which is often a different figure from the one on the landing page.
Self-pay programs changed the comparison
Both manufacturers now sell directly to cash-paying patients at prices well below list. These programs have made brand medication accessible to people who would previously have been priced out, and they have narrowed the gap that used to make compounded alternatives the only realistic option.
They also carry conditions. Refill timing requirements are common, and pricing can vary by dose or by whether you stay enrolled continuously. Missing a refill window can move you to a higher price, so the sustainable monthly figure matters more than the introductory one.
Where compounded medication sits
Compounded semaglutide and tirzepatide are prepared by compounding pharmacies rather than manufactured under an approved application. They are not FDA-approved products, and they have not been through the process that generated the trial evidence for the brands. That is a material distinction, not a technicality.
What compounded products often offer is a predictable monthly cash price without insurance involvement. For people whose plans exclude the category, that predictability is frequently the deciding factor, since an interrupted course produces worse outcomes than a cheaper one sustained. Supervised telehealth providers such as FormBlends publish flat monthly pricing for this reason, with prescribing handled by a licensed clinician rather than sold directly as a product.
The honest framing is that compounded medication trades regulatory assurance for cost predictability. Whether that trade is reasonable depends on the individual, and it is a decision that belongs with a prescriber who knows the case.
Prior authorization is where most of the delay lives
Where a plan does cover the category, approval is rarely automatic. Prior authorization typically requires documentation of body mass index, often a related condition, and sometimes evidence that lifestyle intervention was attempted first. Assembling that paperwork is the step that most often adds weeks between prescription and first dose.
Denials are also frequently appealable, and a meaningful share are overturned when the clinical documentation is completed properly. Treating a first denial as final is a common and expensive mistake. Asking who handles the appeal, and whether the practice does it routinely, is worth doing before choosing a provider rather than after a denial arrives.
Cost drives outcomes more than most comparisons admit
Both drugs show dose-dependent effects and both produce weight regain after discontinuation. That combination means affordability is not a side consideration; it is part of the clinical picture. A person who can sustain a middle dose for two years will usually do better than someone who reaches the top dose for four months and then stops when a deductible resets.
When comparing the two brands on price, compare the figure you can pay every month for as long as treatment continues, not the first month. That single reframing changes the answer for a lot of people.
Comparing that sustainable monthly figure is easier when providers publish it plainly, and they do not all present it the same way. LillyDirect and NovoCare point patients toward the manufacturers’ own self-pay prices for the brands, membership services like Ro and Hims and Hers fold medication into a recurring fee, and telehealth practices such as HealthRX post a Wegovy vs Zepbound price breakdown up front so the number is visible before enrolling. Lining up two or three of these in one sitting shows which route stays affordable once the introductory pricing lapses.
Frequently asked questions
Is one of the two reliably cheaper?
Not in a way that generalizes. Both have list prices above a thousand dollars a month, and the amount an individual pays depends far more on their coverage status and which assistance route they use than on the brand.
Why did my plan deny it when it covers other medication?
Many plans exclude anti-obesity medication as a benefit category. That exclusion applies to the category rather than to a specific drug, so switching brands within the category will usually produce the same denial.
Do savings cards work without insurance?
Generally not in the way advertised. Commercial copay cards usually assume existing commercial coverage and typically exclude people with government insurance. Manufacturer self-pay programs are the route designed for cash payers.
Is compounded medication just a cheaper version of the brand?
No. It is prepared by a compounding pharmacy and is not an FDA-approved product. It may contain the same active molecule, but it has not been through the approval process behind the published trial evidence.
What should be checked before comparing prices at all?
Whether the plan covers medication for chronic weight management. That single answer determines which of the four pricing routes applies, and the brand comparison is only meaningful within one route.
